Zobrazeno 1 - 10
of 15
pro vyhledávání: '"David J. Peace"'
Autor:
Daniel P. Petrylak, Lawrence Fong, Charles G. Drake, Mark N. Stein, Douglas G. McNeel, Ravi A. Madan, James L. Gulley, Neil H. Bander, Tomasz M. Beer, Stacey Harrelson, Philip W. Kantoff, William K. Oh, David J. Peace, Hank Porterfield, Oliver Sartor, Neal D. Shore, Susan F. Slovin, Johannes Vieweg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 4, Iss 1 (2016)
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being invest
Externí odkaz:
https://doaj.org/article/95b49601510e476591b41345b52e8b6d
Publikováno v:
Clinical and Developmental Immunology, Vol 2010 (2010)
Twenty-eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate-specific antigen, PSA146-154, between July 2002 and September 2004 and monitored for c
Externí odkaz:
https://doaj.org/article/801771aef5f84a54b3faf94034b9b5c8
Autor:
Alessia Cimadamore, Michael Hurwitz, Mark Stein, Sabina Signoretti, Jeffrey A Sosman, David F McDermott, Michael B Atkins, Naomi B Haas, Elizabeth R Plimack, Hans Hammers, Mehmet A Bilen, Moshe C Ornstein, David Einstein, Opeyemi A Jegede, Robert Alter, David J Peace, Thomas Denize, Catherine J Wu, David Braun, Paul J Catalano
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background To determine the efficacy and toxicity of nivolumab monotherapy in treatment-naïve patients with non-clear cell renal cell carcinoma (nccRCC) and the efficacy of nivolumab/ipilimumab salvage therapy in patients with tumors unresponsive to
Externí odkaz:
https://doaj.org/article/f31aca68bfec4407896225ae6d30cdbd
Autor:
Michael B. Atkins, Opeyemi A. Jegede, Naomi B. Haas, David F. McDermott, Mehmet A. Bilen, Mark Stein, Jeffrey A. Sosman, Robert Alter, Elizabeth R. Plimack, Moshe Ornstein, Michael Hurwitz, David J. Peace, Sabina Signoretti, Thomas Denize, Alessia Cimadamore, Catherine J. Wu, David Braun, David Einstein, Paul J. Catalano, Hans Hammers
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(25)
PURPOSE To determine the value of tumor cell programmed death-ligand 1 (PD-L1) expression as a predictive biomarker of nivolumab monotherapy efficacy in treatment-naive patients with clear cell renal cell carcinoma (ccRCC) and the efficacy of salvage
Publikováno v:
Nature Genetics. 55:534-535
Autor:
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F McDermott, Mehmet A Bilen, Mark Stein, Jeffrey A Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein, Michael Hurwitz, David J Peace, Sabina Signoretti, Thomas Denize, Alessia Cimadamore, Catherine J Wu, David Braun, David Einstein, Paul J Catalano, Hans Hammers
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e004780
BackgroundTo determine the efficacy and toxicity of nivolumab monotherapy in treatment-naïve patients with non-clear cell renal cell carcinoma (nccRCC) and the efficacy of nivolumab/ipilimumab salvage therapy in patients with tumors unresponsive to
Autor:
Michael B. Atkins, Opeyemi Jegede, David F. McDermott, Naomi B. Haas, Mehmet Asim Bilen, Mark N. Stein, Jeffrey A. Sosman, Elizabeth R. Plimack, Robert S. Alter, Moshe Chaim Ornstein, Michael E. Hurwitz, David J. Peace, David Johnson Einstein, Paul J. Catalano, Hans J. Hammers, Meredith M. Regan
Publikováno v:
Journal of Clinical Oncology. 41:604-604
604 Background: Treatment with immunotherapy can be associated with prolonged disease control after discontinuation without the need for further anticancer therapy. Toxicity from therapy can also persist after cessation. TFS with and without toxicity
Autor:
Yousef Zakharia, Eric A. Singer, Satwik Acharyya, Rohan Garje, Monika Joshi, David J. Peace, Veera Baladandayuthapani, Claudia Laancette, Ilona Kryczek, Weiping Zou, Ajjai Shivaram Alva
Publikováno v:
Journal of Clinical Oncology. 41:696-696
696 Background: Hypomethylating agents (HMA) can augment the anti-tumor immune response. Guadecitabine (G) is a novel HMA shown to induce a dose-dependent decrease of global DNA and gene-specific methylation in pre-clinical models. Methods: This is p
Autor:
Michael B. Atkins, Opeyemi Jegede, Naomi B. Haas, David F. McDermott, Mehmet Asim Bilen, Mark N. Stein, Jeffrey Alan Sosman, Robert S. Alter, Elizabeth R. Plimack, Moshe Chaim Ornstein, Michael E. Hurwitz, David J. Peace, Sabina Signoretti, Thomas Denize, Alessia Cimadamore, David A. Braun, Catherine J. Wu, David Johnson Einstein, Paul J. Catalano, Hans J. Hammers
Publikováno v:
Journal of Clinical Oncology. 40:288-288
288 Background: Nivolumab (nivo) is FDA approved for patients (pts) with VEGFR TKI-resistant RCC and the nivo + ipilimumab (nivo/ipi) combination is FDA approved for treatment naïve pts with IMDC intermediate and poor risk renal cell carcinoma (RCC)
Autor:
Pritesh, Patel, Annie L, Oh, Matthew, Koshy, Karen, Sweiss, Santosh L, Saraf, John G, Quigley, Irum, Khan, Nadim, Mahmud, Eileen, Hacker, Howard, Ozer, David J, Peace, Ralph R, Weichselbaum, Bulent, Aydogan, Damiano, Rondelli
Publikováno v:
Leukemialymphoma. 59(7)
In this phase 1 study, we tested increasing doses of total marrow irradiation (TMI) in addition to standard intravenous melphalan at 200 mg/m